Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
종목 코드 RDY
회사 이름Dr Reddy's Laboratories Ltd
상장일Jan 01, 1986
CEOMr. Deepak Sapra
직원 수27811
유형Ordinary Share
회계 연도 종료Jan 01
주소8-2-337, Road No.3 Banjara Hills
도시HYDERABAD
증권 거래소Australian Stock Exchange Ltd
국가India
우편 번호500034
전화914049002900
웹사이트https://www.drreddys.com/
종목 코드 RDY
상장일Jan 01, 1986
CEOMr. Deepak Sapra
지난 5년 동안 총
332.70M
USD의 배당금이 분배되었습니다.
RDY.NB Final Cash Dividend of gross USD 0.476153 paid on Aug 12, 2024 going ex on Jul 30, 2024
RDY.NB Final Cash Dividend of gross USD 0.482608 paid on Aug 11, 2023 going ex on Jul 28, 2023
RDY.NB Final Cash Dividend of gross USD 0.378434 paid on Aug 12, 2022 going ex on Aug 01, 2022
RDY.NB Final Cash Dividend of gross USD 0.336485 paid on Aug 11, 2021 going ex on Jul 30, 2021
RDY.NB Final Cash Dividend of gross USD 0.333364 paid on Aug 17, 2020 going ex on Jul 10, 2020